Back to Agenda
Session 6 Track B: Data Sharing and Anonymisation
Session Chair(s)
Hans Ulrich Burger, PHD
Senior Director of Biostatistics, F. Hoffmann-La Roche Ltd., Switzerland
Data sharing is a topic which was originally kicked off by the EMA announcement that in future clinical study reports and individual patient data would be released to the public for every submission to ensure full transparency. This initiative triggered an intensive discussion globally. Pharmaceutical companies agreed to provide individual patient level data by themselves to independent researchers. There are significant consequences for the pharmaceutical industry. This concerns their dialogue with physicians, the way clinical study reports will be written, clinical studies designed, what kind of data to be sampled within a trial and last but not least also how patient confidentiality could be protected. It is important to have an overview on all these aspects when conducting studies in the future. This session should provide an overview where we are today as well as on potential consequences.
Speaker(s)
Sally Hollis, MSC
Head of Statistical Consulting , Phastar, United Kingdom
Where we are with Data Sharing and Patient Level Data Sharing in the EU and Industry
Franz Koenig, MSC
Associate Professor, Medical University of Vienna, Austria
Academic and Regulatory Aspects of Data Sharing
Rebecca Sudlow, MS
Global Lead Patient Level Data Sharing, Roche, United Kingdom
Pratical ASpects of Data Sharing, What Does it Mean for Running Trials?
Have an account?
